Format

Send to

Choose Destination
Indian J Ophthalmol. 2019 Sep;67(9):1400-1404. doi: 10.4103/ijo.IJO_2112_18.

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.

Author information

1
Medical Consultant, Department of Cornea and Refractive Surgery, Aravind Eye Hospital, Salem, Tamil Nadu, India.
2
Comprhensive Ophthalmology Fellow, Aravind Eye Hospital, Salem, Tamil Nadu, India.
3
Fellow in the Department of Cornea, Aravind Eye Hospital, Salem, Tamil Nadu, India.
4
Chief Medical Officer, Aravind Eye Hospital, Salem, Tamil Nadu, India.

Abstract

Purpose:

With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic conjunctivitis cases. Hence, we decided to methodically study the efficacy of three topical medications.

Methods:

Prospective, observer-masked clinical trial enrolled 45 patients with 15 patients in each of the three groups. Patients with mild to moderate allergic conjunctivitis were sequentially assigned to respective groups, and relief of symptoms and signs were noted upto 1-month follow-up.

Results:

All three topical medications faired almost equally in resolving symptoms of the patients with mild to moderate allergic conjunctivitis, and most of them reported complete relief after 1 week of use of medication. Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups.

Conclusion:

We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis.

KEYWORDS:

Alcaftadine; allergic conjunctivitis; bepotastine; olopatadine

PMID:
31436181
DOI:
10.4103/ijo.IJO_2112_18
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center